Document is current
Any future updates will be listed below
-
Authors
Ma, Jiaqi https://orcid.org/0000-0002-6298-0193
Ayres, Cory M. https://orcid.org/0000-0001-9846-8020
Brambley, Chad A. https://orcid.org/0000-0001-9429-2048
Chandran, Smita S.
Rosales, Tatiana J.
Perera, W. W. J. Gihan
Eldaly, Bassant https://orcid.org/0009-0009-9532-8546
Murray, William T.
Corcelli, Steven A.
Kovrigin, Evgenii L.
Klebanoff, Christopher A. https://orcid.org/0000-0001-9645-3896
Baker, Brian M. https://orcid.org/0000-0002-0864-0964
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (R35GM118116)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R37CA259177)
- License Information
-
More Information
Article History
Received: 21 May 2024
Accepted: 7 January 2025
First Online: 20 January 2025
Competing interests
: C.A.K. and S.S.C. are inventors of patents related to the T cell receptor (TCR) sequences featured in this manuscript and are recipients of licensing revenue from Intima Bioscience shared according to Memorial Sloan Kettering Cancer Center (MSKCC) institutional policies. C.A.K. has consulted for or is on the scientific advisory boards for Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, Bristol Myers Squibb, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche/Genentech, Royalty Pharma, and T-knife, and is a scientific co-founder and equity holder in Affini-T Therapeutics. S.S.C. is a scientific advisor and equity holder in Affini-T Therapeutics. B.M.B. is an inventor on patents relating to differences between mutant and self in identifying immunogenic neoantigens has consulted for or received funding from Merck, Pfizer, Eureka Therapeutics, and EnaraBio, and is on the scientific advisory board of T-cure Bioscience. The other authors declare no competing interests.
